CTOs on the Move

Achaogen

www.achaogen.com

 
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are anchored in our work by our key values of integrity, accountability, transparency, scientific rigor and drive. We pride ourselves in creating a work community that is patient-centric, scientifically driven, supportive, and collaborative, and that encourages the diversity of thought leading to great innovation. We are always excited to add people to our dynamic team who thrive in our community and who are driven and motivated to transform the lives of patients.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.achaogen.com
  • 7000 & 6000 Shoreline Court #371
    South San Francisco, CA USA 94080
  • Phone: 650.800.3636

Executives

Name Title Contact Details

Funding

Achaogen raised $116.61M on 06/14/2016

Similar Companies

Proclara Biosciences

Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by Alzheimer`s, Parkinson`s, and other diseases caused by protein misfolding. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Chromotrax

Chromotrax is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Navigate BioPharma

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Phosplatin Therapeutics

Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.

Bio-Path Holdings

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.